According to a study published in Annals of Internal Medicine, aspirin may benefit many patients without existing cardiovascular disease. Aspirin reduces the risk of cardiovascular disease but increases the risk for bleeding.
According to a survey, researchers from the University of Auckland found that 43.6 percent of women age from 30 to 79 years without established CVD to identify persons for whom aspirin would probably result in a net benefit. Aspirin was calculated for each participant by decreasing the number of CVD events.
Researchers found that 2.5 percent of women and 12.1 percent of men without established CVD were likely to derive net benefit from aspirin treatment for 5 years. These percentages increased to 21percent of women and 41 percent of men when one CVD event was assumed to be equivalent to two major bleeds.